Zacks Investment Research Upgrades Citius Pharmaceuticals (NASDAQ:CTXR) to “Hold”

Share on StockTwits

Citius Pharmaceuticals (NASDAQ:CTXR) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday, reports.

According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. “

A number of other equities analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating on shares of Citius Pharmaceuticals in a report on Monday, March 1st. Dawson James reissued a “buy” rating and issued a $6.00 price objective on shares of Citius Pharmaceuticals in a research note on Thursday, February 25th.

Shares of Citius Pharmaceuticals stock opened at $2.39 on Monday. Citius Pharmaceuticals has a 12-month low of $0.77 and a 12-month high of $2.90. The company has a 50-day moving average of $1.88 and a two-hundred day moving average of $1.41.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings results on Wednesday, February 10th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.31). As a group, sell-side analysts predict that Citius Pharmaceuticals will post -0.48 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the business. Freed Investment Group bought a new position in Citius Pharmaceuticals in the 4th quarter valued at $29,000. GSA Capital Partners LLP acquired a new stake in shares of Citius Pharmaceuticals in the 4th quarter valued at $35,000. Horst & Graben Wealth Management LLC acquired a new position in shares of Citius Pharmaceuticals during the first quarter valued at $88,000. Wealth Advisory Solutions LLC bought a new stake in Citius Pharmaceuticals during the 4th quarter worth about $107,000. Finally, Virtu Financial LLC boosted its stake in shares of Citius Pharmaceuticals by 24.4% in the 3rd quarter. Virtu Financial LLC now owns 114,223 shares of the company’s stock valued at $119,000 after purchasing an additional 22,430 shares during the last quarter. Hedge funds and other institutional investors own 1.89% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

See Also: How does quantitative easing work?

Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with's FREE daily email newsletter.